http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박보라 ( Bo Ra Park ),전섭 ( Seob Jeon ),배동한 ( Dong Han Bae ),남계현 ( Gye Hyun Nam ),정동준 ( Dong Jun Jeong ) 대한산부인과학회 2012 Obstetrics & Gynecology Science Vol.55 No.1
Papillary squamotransitional cell carcinoma (PSTCC) of vagina is not a common disease. Especially primary neoplasm, which is not associated with carcinoma of urinary tract is very rare. To our knowledge, there have been only three reported cases of primary vaginal PSTCC without the history of urothelial carcinoma. Here, we report primary vaginal PSTCC accompanied by cervical squamous carcinoma in situ without the history of urothelial carcinoma with brief review of literature.
자궁내막암 세포주 Hec-1A에서 sorafenib과 celecoxib에 의한 세포증식억제와 혈관내피성장인자의 발현 변화
김정식 ( Jeong Sig Kim ),박보라 ( Bo Ra Park ),남계현 ( Gye Hyun Nam ),배동한 ( Dong Han Bae ) 대한산부인과학회 2012 Obstetrics & Gynecology Science Vol.55 No.11
목적 자궁내막암 세포주 Hec-1A에서 sorafenib과 celecoxib에 의한 세포증식억제 및 혈관내피성장인자(vascular endothelial growth factor, VEGF)의 발현 변화에 대해 연구하고자 하였다. 연구방법 Hec-1A 세포주에 대한 sorafenib과 celecoxib의 처치 농도와 시간에 따른 세포증식억제 작용을 (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay로 측정하였으며, 또한 위 약제들을 단독 또는 병합투여시 VEGF, p53의 변화를 역전사-중합효소연쇄반응(reverse transcription-polymerase chain reaction)으로 측정하였다. 결과 Sorafenib과 celecoxib 각각을 자궁내막암 세포주인 Hec-1A에 처치 시, sorafenib의 농도를 5 ng/mL, 10 ng/mL, 20 ng/mL, 50 ng/mL로 증가시킬수록 모든 농도에서 의미 있게 점차적으로 세포들의 증식이 억제되었으며, celecoxib는 60 μmol/L의 농도에서부터 통계적으로 유의하게 차이가 났다. Sorafenib 10 ng/mL을 단독 처리하였을 때보다 celecoxib를 병합처리하였을 때 약제 간 상승 작용으로 세포증식억제의 차이가 통계적으로 의미 있게 나타났다(P<0.0001). 혈관신생과 관련된 VEGF는 sorafenib과 celecoxib 두 가지 약제를 동시에 병합시 sorafenib 단독 처치보다 발현감소가 의미 있게 나타났다. 그러나 p53의 경우 sorafenib이나 celecoxib를 각각 또는 병합처리하며 시간과 농도를 다르게 하여도 약제들에 따른 발현의 변화는 나타나지 않았다. 결론 본 연구결과로 sorafenib과 celecoxib의 병합처치에 의해 Hec-1A자궁내막암 세포주의 증식과 VEGF의 발현이 억제되므로, 자궁내막암의 기존 치료요법에 위 약제들이 보조적인 역할을 할 수 있으리라 생각된다. Objective The aim of this study was to investigate whether combination of sorafenib and celecoxib exhibited an anti-tumor efficacy or altered expression of vascular endothelial growth factor (VEGF) in Hec-1A endometrial cancer cell line. Methods To determine whether sorafenib or celecoxib-induced growth inhibition was determined by the (3-[4,5-dimethylthiazol-2-yl]-5-[3- carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay. Expression of VEGF and p53 were evaluated using the reverse transcription polymerase chain reaction. Results Combination of sorafenib 10 ng/mL and celecoxib 50 μmol/L exhibited synergistic inhibitory effects compared to treatment with each agent alone (P <0.0001). VEGF expression was also down regulated after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib in Hec-1A cells. However, there was no alteration of p53 expression in Hec- 1A cells after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib. Conclusion Combination treatment of sorafenib and celecoxib to Hec-1A endometrial cancer cell line revealed the ability to inhibit growth and expression of VEGF.
골반 장기 탈출증의 치료로 시행한 천골가시 인대 고정술에 대한 임상적 고찰
이슬기,남계현,송윤섭,이해혁,전준기,김승형 대한산부인과학회 2000 Obstetrics & Gynecology Science Vol.43 No.8
Objective : To assess the results of the sacrospinous ligament suspension procedure for the treatment of pelvic organ prolapse and vault prolapse following hysterectomy. Methods : A retrospective analysis was performed of forty-six patients from follow-up visits, questionnaires, and chart reviews who underwent sacrospinous ligament suspension in the department of Obstetrics and Gynecology, Soonchunhyang University between September 1996 and January 1999. Clinical data collected included age at surgery, parity, severity of defect at each affected site, presence or absence of prior surgery, functional symptoms, concomitant pelvic reconstructive surgery performed and postoperative complications. Outcome of the procedure was assessed from postoperative visit. Results : Thirty-nine patient(84.8%) had uterine prolapse and seven patients had vaginal vault prolapse(15.2%). According to the POP-Q system approved by ICS, stage III pelvic prolapse was in 29 cases(63%), stage IV in 13 cases(28.3%). Forty-three patients(93.5%) underwent sacrospinous ligament suspension in which sixteen patients(37.2%) had concomitant vaginal hysterectomy with or without anterior or posterior colporraphy as clinically indicated. Two patient(4.3%) underwent vaginal hysterectomy and one patient(2.2%) had abdominal hysterectomy with retropubic urethropexy. ladder neck suspension was performed for six patients(13%). The immediate complications were the arterial ruptures(2 cases) and transient buttock pains(8 cases). The satisfactory results were obtained from 34 cases(85%) and the recurrent vaginal apical prolapse were found in the 2 cases(5%) of the performed patients. Conclusion : The transvaginal sacrospinous ligament suspension is considered to be effective, easy to perform in the treatment of pelvic organ prolapse and vaginal vault prolapse.
포상기태(Hydatidiform mole)에 의해 발생된 심한 갑상선중독증 1예
이재학,박종근,권순효,목지오,윤지성,김여주,박형규,김철희,김상진,이해혁,남계현,권계현,고은석,변동원,서교일,유명희 대한내분비학회 2003 Endocrinology and metabolism Vol.18 No.4
저자들은 무월경의 11주의 27세 환자에서 심한 갑상선중독증을 동반하고, β-HCG가 1,123,0001U/L으로 크게 증가되었으나, 흡입소파술 시행후 임상 증상과 갑상선기능 그리고 β-HCG가 모두 정상으로 호전된 포상기태 (Hydatidiform mole) 1예를 경험하였기에 문헌 고찰과 함께 보고하는 바이다. Human chorionic gonadotropin(HCG) is one of the glycoproteins families synthesized by the placenta, and consists of 2 noncovalently joined subunits, namely, α' and . The α' and -subunits have a structural homology with the α' and -subunits of TSH and LH. The thyrotropic action of HCG results from its structural similarity to TSH, so -HCG can bind to the TSH receptor in the thyroid gland. A high level of HCG, accompanied by an increased thyroid hormone level, can be observed in gestational trophoblastic diseases (GTD), such as a hydatidiform mole or a chorio- carcinoma. However, the clinical symptoms of hyperthyroidism in GTD are rarely observed. A 27-years-old woman, admitted due to an amenorrhea of 11 weeks duration, with thyrotoxic symptoms, such as weight loss, palpitation, sweating, tremor, heat intolerance and anxiety, was evaluated. Her serum free T4 level was 8 times higher than normal, and her serum -HCG level was over l,OO0,00OIU/L. She had a curettage operation, with the pathological findings of a complete hydatidiform mole. These thyrotoxic symptoms developed due to a hydatidiform mole, and were accompanied with a highly increased serum β-HCG level. After evacuation of the molar tissue, the thyroid hormone and thyrotoxic symptoms normalized. Here, this case is reported, with brief review of the literature (J Kor SOC Endocrinol 18:420425, 2003).